Drug
Blinatumomab clinical trials
Also written Blincyto, AMG 103 and MT103.
- studies test it
- 129
- open now
- 58
- in phase 3
- 23
- first study started
- 2004
Keep track of what changes. Save the blinatumomab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Blinatumomab
- 112
Brand
- Blincyto
- 59
Studies by the year they started
127 studies that test it; most in 2017 (15); 2 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 15 |
| 2018 | 12 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 11 |
| 2022 | 6 |
| 2023 | 9 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 35
- Phase 2
- 82
- Phase 3
- 23
- Phase 4
- 3
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 99
Amgen (19) · M.D. Anderson Cancer Center (12) · Institute of Hematology & Blood Diseases Hospital, China (9) · National Cancer Institute (NCI) (7) · Amgen Research (Munich) GmbH (7) · St. Jude Children's Research Hospital (5) · Goethe University (4) · The First Affiliated Hospital of Soochow University (4)
Often tested with
Tested in the same studies.
Venetoclax (10) · Inotuzumab Ozogamicin (9) · Prednisone (7) · Cyclophosphamide (6) · Cytarabine (6) · Dexamethasone (6) · Methotrexate (6) · Mercaptopurine (5)
Studies
Open first, then newest update. How each study uses blinatumomab is read from its arms, and is right about nine times in ten.
Testing it · 129
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Blinatumomab
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaRecruitingPhase 3Princess Maxima Center for Pediatric OncologyNCT05327894Written as Blinatumomab
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07133997Written as Blinatumomab
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Blinatumomab
- Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic LeukemiaRecruitingPhase 2Northside Hospital, Inc.NCT05519579Written as Blinatumomab
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06308588Written as Blinatumomab
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07178912Written as Blinatumomab
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingPhase 2AmgenNCT06570798Written as Blinatumomab
- Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's SyndromeNot yet recruitingPhase 2Beijing Tongren HospitalNCT07852234Written as Blinatumomab
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as Blinatumomab
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Blinatumomab
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaNot yet recruitingPhase 3AmgenNCT07223190Written as Blinatumomab
- Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07003737Written as Blinatumomab
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Blinatumomab
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07283640Written as Blinatumomab
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingPhase 3Mats HeymanNCT04307576Written as Blinatumomab
- A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07313852Written as Blinatumomab Injection
- Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06287229Written as Blinatumomab
- A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07723911Written as Blinatumomab for Injection
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingPhase 2/3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06764238Written as Blinatumomab (Group A)
See all 129 studies that test blinatumomab →
Given in every arm · 17 — blinatumomab is usual care beside what is tested
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Blinatumomab
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Blinatumomab
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Blinatumomab
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Blinatumomab
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Blinatumomab
- ALL Backbone in AYAsRecruitingPhase 2Dana-Farber Cancer InstituteNCT07227584Written as Blinatumomab
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07495631Written as Blinatumomab
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07493161Written as Blinatumomab
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT01371630Written as Blinatumomab
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07454226Written as Blinatumomab
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07573670Written as Blinatumomab
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677Written as Blinatumomab
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingPhase 1Ascentage Pharma Group Inc.NCT04260022Written as Blinatumomab
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Blinatumomab
- Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual DiseaseCompletedPhase 2M.D. Anderson Cancer CenterNCT02458014Written as Blinatumomab
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07153796Written as Blinatumomab
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02143414Written as Blinatumomab
As the comparator · 3 — what is tested is compared with blinatumomab
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Blinatumomab
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07570173Written as Blinatumomab
- Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaWithdrawnPhase 3Novartis PharmaceuticalsNCT03628053Written as Blinatumomab
Codes
What other systems call blinatumomab · ClinicalTrials.gg INT004918
- MeSH (NLM) C510808blinatumomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4FR53SIF3ABLINATUMOMABConfirmed FDA, NLM, Wikidata
- RxNorm 1597258Confirmed FDA, Wikidata
- Wikidata Q410189blinatumomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62528BlinatumomabOne source FDA
- DrugBank DB09052One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510808 | blinatumomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4FR53SIF3A | BLINATUMOMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597258 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410189 | blinatumomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62528 | Blinatumomab | One source FDA |
| DrugBank | DB09052 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.